Sublingual Sufentanil PCA Usability for Postoperative Pain (Zalviso® System)

CompletedOBSERVATIONAL
Enrollment

119

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

May 24, 2019

Study Completion Date

May 24, 2019

Conditions
TraumaSurgery
Interventions
DEVICE

Zalviso Device

"The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program."

Trial Locations (1)

69004

Hôpital de la Croix Rousse - Service d'Anesthésie-Réanimation, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03373851 - Sublingual Sufentanil PCA Usability for Postoperative Pain (Zalviso® System) | Biotech Hunter | Biotech Hunter